title: Changes of venous blood flow velocity waveforms in fetuses with supraventricular tachycardia.
abstract: Studies in the fetal lamb have shown that atrial pacing beyond a rate of 300-320 beats/min may be associated with dramatic changes of venous blood velocity waveforms, an increase of venous pressure by up to 75%, hydrops, polyhydramnios and placental edema. The aim of our study was to determine the 'critical' heart rate frequency in the human fetus. In 11 fetuses (five with and six without hydrops) with supraventricular tachycardia, pulsed wave Doppler analysis of flow velocity waveforms of the inferior vena cava, the ductus venosus and the left hepatic vein were performed before and after drug treatment. In ten cases cardioversion was achieved by in utero antiarrhythmic drug therapy; in one case treated with digoxin and flecainide the supraventricular tachycardia was decreased to 160-190 beats/min with disappearance of hydrops. Before intrauterine treatment of supraventricular tachycardia, pulsatile reversal of blood flow in the inferior vena cava, ductus venosus and left hepatic vein was visible, with monophasic forward flow during systole and reversed flow during diastole in ten of 11 fetuses. One fetus with supraventricular tachycardia of 195 beats/min showed a normal biphasic forward flow pattern. During drug-induced sinus rhythm, a normal biphasic forward venous blood flow pattern was shown in all ten cases. In five cases pulsatile reversal was demonstrated during a drug-induced reduction of the heart rate from 280 to 210 beats/min and a normal biphasic forward flow velocity waveform appeared during supraventricular tachycardia below 210 beats/min.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Obstetrics and Gynecology, Medical University of Lübeck, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Gembruch
authors.forename: M
authors.initials: M
authors.lastname: Krapp
authors.forename: P
authors.initials: P
authors.lastname: Baumann
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001783:Blood Flow Velocity / Q000502:physiology; D005260:Female; D005312:Fetal Blood / Q000000981:diagnostic imaging / Q000502:physiology; D005315:Fetal Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D005865:Gestational Age; D006340:Heart Rate, Fetal; D006503:Hepatic Veins / Q000000981:diagnostic imaging / Q000196:embryology / Q000502:physiology*; D006801:Humans; D015160:Hydrops Fetalis / Q000503:physiopathology; D008099:Liver / Q000098:blood supply / Q000000981:diagnostic imaging / Q000196:embryology; D011247:Pregnancy; D011673:Pulsatile Flow; D013617:Tachycardia, Supraventricular / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D018615:Ultrasonography, Doppler, Color; D016216:Ultrasonography, Prenatal; D014682:Vena Cava, Inferior / Q000000981:diagnostic imaging / Q000196:embryology / Q000502:physiology*
chemical_list: D000889:Anti-Arrhythmia Agents